Optimizing Treatment for HIV-Infected South African Women Exposed to Single-Dose Nevirapine: Balancing Efficacy and Cost | Zendy

Charles B. Holmes | Zendy; Hui Zheng | Zendy; Neil Martinson | Zendy; Kenneth A. Freedberg | Zendy; Rochelle P. Walensky | Zendy

Open Access

Optimizing Treatment for HIV-Infected South African Women Exposed to Single-Dose Nevirapine: Balancing Efficacy and Cost

Author(s) -

Charles B. Holmes,

Hui Zheng,

Neil Martinson,

Kenneth A. Freedberg,

Rochelle P. Walensky

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/504382

Subject(s) - lopinavir , nevirapine , ritonavir , medicine , regimen , lopinavir/ritonavir , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , virology

Nevirapine (NVP) resistance may decrease the effectiveness of viral suppression with NVP-based antiretroviral therapy (ART) in women infected with human immunodeficiency virus (HIV) with previous exposure to single-dose NVP. However, the alternative lopinavir-ritonavir-based ART regimen is more expensive. Our objectives were to project the tradeoffs regarding life expectancy, cost, and cost-effectiveness of these ART regimens for NVP-exposed, HIV-infected women in South Africa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research